<DOC>
	<DOCNO>NCT00583674</DOCNO>
	<brief_summary>This phase 2 , randomize , double blind , placebo control , multi-center study estimate improvement progression free survival ( compare control subject ) evaluate safety tolerability AMG 386 combination Cisplatin &amp; Capecitabine treatment subject Metastatic Gastric , Gastroesophageal Junction , Distal Esophageal Adenocarcinoma . AMG 386 man-made medication design stop development blood vessel cancer tissue . Cancer tissue rely development new blood vessel , process call angiogenesis , obtain supply oxygen nutrient grow .</brief_summary>
	<brief_title>Phase 2 Study AMG 386 ( 20060439 ) Combination With Cisplatin &amp; Capecitabine Subjects With Metastatic Gastric , Gastroesophageal Junction , Distal Esophageal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Disease Related Histologically cytologically confirm adenocarcinoma stomach , gastroesophageal junction distal esophagus metastatic disease Measurable nonmeasurable disease per RECIST Guidelines Prior gastrectomy ( total partial ) may allow long subject take oral medication meet inclusion/exclusion criterion . Subjects may take crushed dissolve capecitabine via feeding/gastrostomy tube Palliative radiotherapy metastatic esophageal gastric cancer prior study entry may allow long toxicity radiotherapy resolve radiotherapy site know metastatic disease Demographic •18 year age old time write informed consent obtain General Able swallow oral medication ECOG performance status 0 1 Laboratory Adequate organ hematological function evidence laboratory study prior randomization Disease Related Prior chemotherapy metastatic disease ( 1st line ) Less 12 month elapse completion previous adjuvant neoadjuvant chemotherapy chemoradiotherapy Subjects persistent gastric outlet obstruction , complete dysphagia feed jejunostomy Radiotherapy ≤ 14 day prior randomization . Subjects must recover radiotherapyrelated toxicity Current prior history central nervous system metastases History arterial deep venous thromboembolism within 12 month prior randomization History bleed diathesis clinically significant bleeding within 6 month prior randomization Major surgical procedure within 28 day prior randomization Minor surgical procedure , placement central venous access device fine needle aspiration within 3 day prior randomization Prior malignancy except : malignancy treat curative intent without evidence active disease ≥ 3 year prior randomization felt low risk recurrence treat physician , adequately treat nonmelanomatous skin cancer lentigo maligna without evidence disease , adequately treated cervical carcinoma situ without evidence disease , prostatic intraepithelial neoplasia without evidence prostate cancer Prior malignancy ( situ cervical cancer , basal cell cancer skin ) unless treat curative intent without evidence disease ≥ 3 year prior randomization Clinically significant cardiovascular disease within 12 month prior randomization Presence clinically significant nonhealing wound , ulcer ( include gastrointestinal ) fracture judge investigator Ongoing clinically significant active infection judge investigator Known hypersensitivity bacterial protein , drug require study Known peripheral neuropathy ≥Grade 1 Known dihydropyrimidine dehydrogenase deficiency Known hypersensitivity 5FU/capecitabine Known positive test human immunodeficiency virus ( HIV ) , hepatitis C , hepatitis B surface antigen Known active chronic hepatitis Medications Currently previously treat angiopoietin inhibitor , inhibitor TIE1 TIE2 Treatment immune modulators cyclosporine tacrolimus within 30 day prior randomization Treatment sorivudine chemically related analogue Anticoagulants ( aspirin antiplatelet agent ) within 7 day prior randomization . The concurrent use low molecular weight heparin heparanoids low dose warfarin ( i.e , ≤ 1 mg daily ) prophylaxis thrombosis acceptable study General Not yet complete least 30 day since end investigational device/drug trial ( ) , subject receive investigational treatment Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Metastatic Gastric , Gastroesophageal Junction , Distal Esophageal Adenocarcinoma</keyword>
	<keyword>AMG 386</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Capecitabine</keyword>
</DOC>